TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,028,613 | +63.2% | 2,240,337 | +180.5% | 0.00% | +100.0% |
| Q2 2023 | $12,269,246 | -39.0% | 798,779 | -10.6% | 0.00% | -50.0% |
| Q1 2023 | $20,103,137 | +38.1% | 893,870 | +29.1% | 0.00% | 0.0% |
| Q4 2022 | $14,557,050 | +58.4% | 692,204 | +85.5% | 0.00% | +100.0% |
| Q3 2022 | $9,192,000 | -35.2% | 373,068 | -36.3% | 0.00% | -50.0% |
| Q2 2022 | $14,192,000 | +13.3% | 585,773 | +20.5% | 0.00% | 0.0% |
| Q1 2022 | $12,522,000 | +29.4% | 485,942 | +55.8% | 0.00% | +100.0% |
| Q4 2021 | $9,679,000 | +4.8% | 311,807 | -18.1% | 0.00% | 0.0% |
| Q3 2021 | $9,237,000 | +361.6% | 380,935 | +177.9% | 0.00% | – |
| Q2 2021 | $2,001,000 | +204.6% | 137,083 | +419.8% | 0.00% | – |
| Q1 2021 | $657,000 | -59.9% | 26,373 | -56.1% | 0.00% | – |
| Q4 2020 | $1,637,000 | – | 60,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |